CA2671961A1 - Administration retinienne d'un acide nucleique amelioree par ionophorese - Google Patents

Administration retinienne d'un acide nucleique amelioree par ionophorese Download PDF

Info

Publication number
CA2671961A1
CA2671961A1 CA002671961A CA2671961A CA2671961A1 CA 2671961 A1 CA2671961 A1 CA 2671961A1 CA 002671961 A CA002671961 A CA 002671961A CA 2671961 A CA2671961 A CA 2671961A CA 2671961 A1 CA2671961 A1 CA 2671961A1
Authority
CA
Canada
Prior art keywords
iontophoresis
nucleic acid
rdl
injection
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002671961A
Other languages
English (en)
Inventor
Therese De Bizemont
Florian Sennlaub
Francine Behar-Cohen
Yves Courtois
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EyeGate Pharma SAS
Original Assignee
EyeGate Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EyeGate Pharma SAS filed Critical EyeGate Pharma SAS
Publication of CA2671961A1 publication Critical patent/CA2671961A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
CA002671961A 2006-12-05 2007-12-05 Administration retinienne d'un acide nucleique amelioree par ionophorese Abandoned CA2671961A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87323306P 2006-12-05 2006-12-05
US60/873,233 2006-12-05
PCT/IB2007/004565 WO2008125908A2 (fr) 2006-12-05 2007-12-05 Administration rétinienne d'un acide nucléique améliorée par ionophorèse

Publications (1)

Publication Number Publication Date
CA2671961A1 true CA2671961A1 (fr) 2008-10-23

Family

ID=39864419

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002671961A Abandoned CA2671961A1 (fr) 2006-12-05 2007-12-05 Administration retinienne d'un acide nucleique amelioree par ionophorese

Country Status (4)

Country Link
EP (1) EP2099497A2 (fr)
JP (1) JP2010511692A (fr)
CA (1) CA2671961A1 (fr)
WO (1) WO2008125908A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009293658A1 (en) 2008-09-22 2010-03-25 James Cardia Reduced size self-delivering RNAi compounds
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
EP2550001B1 (fr) 2010-03-24 2019-05-22 Phio Pharmaceuticals Corp. Arn interférant dans des indications oculaires
WO2011119852A1 (fr) 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Composés d'arni de taille réduite s'auto-administrant
WO2015044704A1 (fr) * 2013-09-30 2015-04-02 Sanofi Utilisation d'un agoniste de neuroglobuline pour prévenir ou traiter des maladies mitochondriales dues à une déficience de rcciii et/ou rcci
WO2015168108A2 (fr) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Procédés de traitement du cancer au moyen d'un acide nucléique deciblage de mdm2 ou mycn
JP2018502639A (ja) 2015-01-22 2018-02-01 アイゲート ファーマスーティカルズ，インコーポレイテッド イオントフォレシスコンタクトレンズ

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045830A1 (en) * 2001-04-17 2003-03-06 De Bizemont Therese Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis
JP2007532662A (ja) * 2004-04-13 2007-11-15 （オーエスアイ）アイテツク・インコーポレーテツド 高分子量の立体的な基へ抱合された核酸アプタマー
WO2006072887A1 (fr) * 2005-01-05 2006-07-13 Eyegate Pharma Sa Dispositif d'iontophorese oculaire distribuant du petit arn interferent et des aptameres

Also Published As

Publication number Publication date
EP2099497A2 (fr) 2009-09-16
JP2010511692A (ja) 2010-04-15
WO2008125908A2 (fr) 2008-10-23
WO2008125908A3 (fr) 2009-04-09

Similar Documents

Publication Publication Date Title
US20090088721A1 (en) Enhanced retinal delivery of a nucleic acid through iontophoresis
Bloquel et al. Non-viral ocular gene therapy: potential ocular therapeutic avenues
JP5000638B2 (ja) 対象の眼球に対して治療用生成物を送達するための改良型方法及び装置
Andrieu-Soler et al. Ocular gene therapy: a review of nonviral strategies
Rossmiller et al. Gene therapy in animal models of autosomal dominant retinitis pigmentosa
US20090011040A1 (en) Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
CA2671961A1 (fr) Administration retinienne d'un acide nucleique amelioree par ionophorese
Hao et al. Gene delivery to cornea
US20210290433A1 (en) Intraocular delivery of gene therapy expression vectors
US20030045830A1 (en) Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis
Asahara et al. Induction of gene into the rabbit eye by iontophoresis: preliminary report
Isaka Gene therapy targeting kidney diseases: routes and vehicles
US11883541B2 (en) Nonviral gene transfer to the suprachoroidal space
US11752220B2 (en) Method of delivering genes and drugs to a posterior segment of an eye
WO2011017313A1 (fr) Procédé d'administration de vecteurs d'acide nucléique non viraux à l'œil
EP2418279A1 (fr) Composition pharmaceutique injectable pour prévenir, stabiliser et/ou inhiber des états liés à une néovascularisation pathologique
WO2023165583A1 (fr) Système et procédé d'administration ciblant une cellule oculaire
US20220273694A1 (en) Compositions and methods for decreasing intraocular pressure
US20240156638A1 (en) Devices and methods for electrotransfer
US11981911B2 (en) Compositions and methods for inhibiting viral vector-induced inflammatory responses
US9315829B2 (en) Methods for intracellular delivery of nucleic acids
WO2024064608A2 (fr) Vecteurs de best1 et leurs utilisations
US20200270637A1 (en) Compositions and methods for inhibiting viral vector-induced inflammatory responses
AU721060B2 (en) Hyaluronic acid as DNA carrier for gene therapy and VEGF antisense DNA to treat abnormal retinal vascularization
Shukla et al. Site-Specific Ocular Nucleic Acid Delivery

Legal Events

Date Code Title Description
FZDE Dead